These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 30036202)

  • 1. Medical management of aortic disease in children with Marfan syndrome.
    Lindsay ME
    Curr Opin Pediatr; 2018 Oct; 30(5):639-644. PubMed ID: 30036202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations.
    Gambarin FI; Favalli V; Serio A; Regazzi M; Pasotti M; Klersy C; Dore R; Mannarino S; Viganò M; Odero A; Amato S; Tavazzi L; Arbustini E
    J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):354-62. PubMed ID: 19430350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review of the pharmacological management of aortic root dilation in Marfan syndrome.
    Thakur V; Rankin KN; Hartling L; Mackie AS
    Cardiol Young; 2013 Aug; 23(4):568-81. PubMed ID: 23083542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AT1 receptor antagonism to reduce aortic expansion in Marfan syndrome: lost in translation or in need of different interpretation?
    Mallat Z; Daugherty A
    Arterioscler Thromb Vasc Biol; 2015 Feb; 35(2):e10-2. PubMed ID: 25550201
    [No Abstract]   [Full Text] [Related]  

  • 5. Update on Clinical Trials of Losartan With and Without β-Blockers to Block Aneurysm Growth in Patients With Marfan Syndrome: A Review.
    Hofmann Bowman MA; Eagle KA; Milewicz DM
    JAMA Cardiol; 2019 Jul; 4(7):702-707. PubMed ID: 31066871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis Examining the Usefulness of Angiotensin Receptor blockers for the Prevention of Aortic Root Dilation in Patients With the Marfan Syndrome.
    Al-Abcha A; Saleh Y; Mujer M; Boumegouas M; Herzallah K; Charles L; Elkhatib L; Abdelkarim O; Kehdi M; Abela GS
    Am J Cardiol; 2020 Aug; 128():101-106. PubMed ID: 32650901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Novel pharmacological strategies for aortic dilation in Marfan syndrome: from mouse models to human patients].
    Perrino C; Schiattarella GG; Bottino R; Magliulo F; Oliveti M; Esposito G; Trimarco B
    G Ital Cardiol (Rome); 2014; 15(7-8):408-17. PubMed ID: 25174594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective, randomized, placebo-controlled, double-blind, multicenter study of the effects of irbesartan on aortic dilatation in Marfan syndrome (AIMS trial): study protocol.
    Mullen MJ; Flather MD; Jin XY; Newman WG; Erdem G; Gaze D; Valencia O; Banya W; Foley CE; Child A
    Trials; 2013 Dec; 14():408. PubMed ID: 24289736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent Clinical Drug Trials Evidence in Marfan Syndrome and Clinical Implications.
    Singh MN; Lacro RV
    Can J Cardiol; 2016 Jan; 32(1):66-77. PubMed ID: 26724512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome.
    Habashi JP; Judge DP; Holm TM; Cohn RD; Loeys BL; Cooper TK; Myers L; Klein EC; Liu G; Calvi C; Podowski M; Neptune ER; Halushka MK; Bedja D; Gabrielson K; Rifkin DB; Carta L; Ramirez F; Huso DL; Dietz HC
    Science; 2006 Apr; 312(5770):117-21. PubMed ID: 16601194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Losartan therapy in adults with Marfan syndrome: study protocol of the multi-center randomized controlled COMPARE trial.
    Radonic T; de Witte P; Baars MJ; Zwinderman AH; Mulder BJ; Groenink M;
    Trials; 2010 Jan; 11():3. PubMed ID: 20067609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medicine. Old drug, new hope for Marfan syndrome.
    Travis J
    Science; 2006 Apr; 312(5770):36-7. PubMed ID: 16601163
    [No Abstract]   [Full Text] [Related]  

  • 13. The Ghent Marfan Trial--a randomized, double-blind placebo controlled trial with losartan in Marfan patients treated with β-blockers.
    Möberg K; De Nobele S; Devos D; Goetghebeur E; Segers P; Trachet B; Vervaet C; Renard M; Coucke P; Loeys B; De Paepe A; De Backer J
    Int J Cardiol; 2012 Jun; 157(3):354-8. PubMed ID: 21239069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome.
    Lacro RV; Dietz HC; Wruck LM; Bradley TJ; Colan SD; Devereux RB; Klein GL; Li JS; Minich LL; Paridon SM; Pearson GD; Printz BF; Pyeritz RE; Radojewski E; Roman MJ; Saul JP; Stylianou MP; Mahony L;
    Am Heart J; 2007 Oct; 154(4):624-31. PubMed ID: 17892982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct effects of losartan and atenolol on vascular stiffness in Marfan syndrome.
    Bhatt AB; Buck JS; Zuflacht JP; Milian J; Kadivar S; Gauvreau K; Singh MN; Creager MA
    Vasc Med; 2015 Aug; 20(4):317-25. PubMed ID: 25795452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-based cardiovascular prevention in patients with Marfan Syndrome: a systematic review.
    Pavasini R; Sanguettoli F; Deserio MA; Bianchi N; Zanarelli L; Fabbri G; Tonet E; Passarini G; Serenelli M; Campo G
    Minerva Cardiol Angiol; 2023 Dec; 71(6):611-621. PubMed ID: 36939732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of losartan as add-on therapy to prevent aortic growth and ventricular dysfunction in patients with Marfan syndrome: a randomized, double-blind clinical trial.
    Muiño-Mosquera L; De Nobele S; Devos D; Campens L; De Paepe A; De Backer J
    Acta Cardiol; 2017 Dec; 72(6):616-624. PubMed ID: 28657492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensin II receptor blocker therapy versus placebo in individuals with Marfan syndrome.
    Detaint D; Aegerter P; Tubach F; Hoffman I; Plauchu H; Dulac Y; Faivre LO; Delrue MA; Collignon P; Odent S; Tchitchinadze M; Bouffard C; Arnoult F; Gautier M; Boileau C; Jondeau G
    Arch Cardiovasc Dis; 2010 May; 103(5):317-25. PubMed ID: 20619242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of losartan versus beta-blockers on cardiovascular protection in marfan syndrome: A systematic review and meta-analysis.
    Kang YN; Chi SC; Wu MH; Chiu HH
    J Formos Med Assoc; 2020 Jan; 119(1 Pt 1):182-190. PubMed ID: 31003918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical treatment of Marfan syndrome: a time for change.
    Williams A; Davies S; Stuart AG; Wilson DG; Fraser AG
    Heart; 2008 Apr; 94(4):414-21. PubMed ID: 18347371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.